Cohort composition
| N | Percentage | |
| Sex | ||
| Male | 145 | 48.70 |
| Female | 153 | 51.30 |
| Median age | 46 years | |
| Median disease duration | 7 years | |
| Diagnosis | ||
| CD | 144 | 48.30 |
| UC | 136 | 45.60 |
| IBD-U | 18 | 6 |
| UC/IBD-U extent | ||
| E1 (proctitis) | 22 | 14.40 |
| E2 (left-sided colitis) | 82 | 53.60 |
| E3 (extensive colitis) | 49 | 32.00 |
| Unknown | 1 | |
| CD phenotype | ||
| A1 (<16 years at diagnosis) | 6 | 4.20 |
| A2 (17–40 years) | 108 | 75.00 |
| A3 (>40 years) | 30 | 20.80 |
| L1 (ileal) | 47 | 32.90 |
| L2 (colonic) | 37 | 25.90 |
| L3 (ileo-colonic) | 59 | 41.20 |
| L4 (upper GI, isolated and/or modifier) | 13 | 9.00 |
| L not known | 1 | |
| B1 (inflammatory) | 69 | 47.90 |
| B2 (structuring) | 41 | 28.50 |
| B3 (penetrating) | 34 | 23.60 |
| Perianal disease | 35 | 32.10 |
| Previous IBD-related surgery | 70 | 23.50 |
| Mesalazine | ||
| Previous | 95 | 31.90 |
| Current | 132 | 44.30 |
| Thiopurines | ||
| Previous | 97 | 32.60 |
| Current | 91 | 30.50 |
| Methotrexate | ||
| Previous | 10 | 3.40 |
| Current | 8 | 2.70 |
| First anti-TNF | ||
| Previous | 45 | 15.10 |
| Current | 60 | 20.10 |
| Second anti-TNF | ||
| Previous | 7 | 2.30 |
| Current | 18 | 6.00 |
CD, Crohn’s disease; IBD, inflammatory bowel disease; TNF, tumour necrosis factor; UC, ulcerative colitis.